JP2018533589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533589A5 JP2018533589A5 JP2018522753A JP2018522753A JP2018533589A5 JP 2018533589 A5 JP2018533589 A5 JP 2018533589A5 JP 2018522753 A JP2018522753 A JP 2018522753A JP 2018522753 A JP2018522753 A JP 2018522753A JP 2018533589 A5 JP2018533589 A5 JP 2018533589A5
- Authority
- JP
- Japan
- Prior art keywords
- plasminogen
- subject
- drug
- days
- deficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013566 Plasminogen Human genes 0.000 claims 86
- 108010051456 Plasminogen Proteins 0.000 claims 86
- 230000000694 effects Effects 0.000 claims 38
- 239000003814 drug Substances 0.000 claims 35
- 229940079593 drug Drugs 0.000 claims 28
- 230000002950 deficient Effects 0.000 claims 25
- 239000000126 substance Substances 0.000 claims 10
- 230000037396 body weight Effects 0.000 claims 8
- 230000007812 deficiency Effects 0.000 claims 6
- 230000003442 weekly effect Effects 0.000 claims 6
- 230000002354 daily effect Effects 0.000 claims 5
- 239000003146 anticoagulant agent Substances 0.000 claims 4
- 230000009469 supplementation Effects 0.000 claims 4
- 230000002537 thrombolytic effect Effects 0.000 claims 4
- 108700036309 Type I Plasminogen Deficiency Proteins 0.000 claims 3
- 208000007788 Acute Liver Failure Diseases 0.000 claims 2
- 206010000804 Acute hepatic failure Diseases 0.000 claims 2
- 208000007257 Budd-Chiari syndrome Diseases 0.000 claims 2
- 206010049811 Extraskeletal ossification Diseases 0.000 claims 2
- 208000034970 Heterotopic Ossification Diseases 0.000 claims 2
- 208000021798 Hypoplasminogenemia Diseases 0.000 claims 2
- 208000011200 Kawasaki disease Diseases 0.000 claims 2
- 208000020165 Neonatal respiratory disease Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000004276 hyalin Anatomy 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000013223 septicemia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 206010071570 ligneous conjunctivitis Diseases 0.000 claims 1
- 230000001502 supplementing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250235P | 2015-11-03 | 2015-11-03 | |
| US62/250,235 | 2015-11-03 | ||
| PCT/IB2016/001599 WO2017077380A1 (en) | 2015-11-03 | 2016-11-03 | Plasminogen replacement therapy for plasminogen-deficiency |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533589A JP2018533589A (ja) | 2018-11-15 |
| JP2018533589A5 true JP2018533589A5 (enExample) | 2019-12-12 |
| JP6878423B2 JP6878423B2 (ja) | 2021-05-26 |
Family
ID=58661917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522753A Active JP6878423B2 (ja) | 2015-11-03 | 2016-11-03 | プラスミノーゲン欠損症のためのプラスミノーゲン補充療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11291711B2 (enExample) |
| EP (1) | EP3370760B1 (enExample) |
| JP (1) | JP6878423B2 (enExample) |
| KR (1) | KR102821400B1 (enExample) |
| CN (1) | CN108289935A (enExample) |
| AU (1) | AU2016347863B2 (enExample) |
| BR (1) | BR112018008965A8 (enExample) |
| CA (1) | CA3002915C (enExample) |
| FI (1) | FI3370760T3 (enExample) |
| IL (1) | IL258913B (enExample) |
| MX (1) | MX2018005588A (enExample) |
| MY (1) | MY199581A (enExample) |
| RU (1) | RU2736831C2 (enExample) |
| TW (1) | TWI801331B (enExample) |
| WO (1) | WO2017077380A1 (enExample) |
| ZA (1) | ZA201802820B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201722464A (zh) * | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| EP3391902B1 (en) * | 2015-12-18 | 2023-10-18 | Talengen International Limited | Plasminogen for use in the treatment of diabetic angiocardiopathy |
| CN109069567A (zh) | 2015-12-18 | 2018-12-21 | 泰伦基国际有限公司 | 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 |
| CN108778307A (zh) | 2015-12-18 | 2018-11-09 | 泰伦基国际有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| CN115845037A (zh) * | 2015-12-18 | 2023-03-28 | 泰伦基国际有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
| WO2017161354A1 (en) * | 2016-03-17 | 2017-09-21 | Vanderbilt University | Enhancing plasmin activity to prevent soft tissue calcification |
| US11389515B2 (en) * | 2016-12-15 | 2022-07-19 | Talengen International Limited | Method for mitigating heart disease |
| TW201822809A (zh) | 2016-12-15 | 2018-07-01 | 深圳瑞健生命科學硏究院有限公司 | 一種預防和治療高脂血症的方法 |
| WO2018108161A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法和药物 |
| EP3556380A4 (en) * | 2016-12-15 | 2020-05-13 | Talengen International Limited | METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN |
| TWI763680B (zh) | 2016-12-15 | 2022-05-11 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備藥物中的用途 |
| CN109125715A (zh) * | 2017-06-19 | 2019-01-04 | 深圳瑞健生命科学研究院有限公司 | 一种调控glp-1/glp-1r的方法和药物 |
| ES3036897T3 (en) | 2017-06-19 | 2025-09-25 | Talengen Int Ltd | Plasminogen for use in treating parkinson's and alzheimer's disease |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| CA3127375A1 (en) * | 2019-01-24 | 2020-07-30 | Previpharma Consulting Gmbh | Plasminogen for treating and preventing microthrombosis |
| EP3812772B1 (en) * | 2019-10-24 | 2025-02-19 | Hôpitaux Universitaires de Strasbourg (HUS) | Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps |
| WO2021214320A1 (en) | 2020-04-23 | 2021-10-28 | Previpharma Consulting Gmbh | Plasminogen for use in treating and preventing lung dysfunction |
| CN114354929A (zh) * | 2022-01-07 | 2022-04-15 | 南京鼓楼医院 | 一种用于监测人体纤溶状态的试剂盒及应用 |
| WO2025049724A1 (en) * | 2023-08-29 | 2025-03-06 | Board Of Regents Of The University Of Nebraska | Compositions and methods for treating pleural space infections and hemothorax |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2254316B1 (enExample) * | 1973-12-18 | 1977-04-22 | Choay Sa | |
| JP2764264B2 (ja) * | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
| AT402367B (de) * | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
| AU4661493A (en) * | 1992-07-01 | 1994-01-31 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
| WO1994018315A1 (en) * | 1993-02-05 | 1994-08-18 | Vascular Laboratories, Inc. | Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis |
| US20030224516A1 (en) * | 2002-06-03 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of prox-1 expression |
| US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| US20050271636A1 (en) * | 2002-08-09 | 2005-12-08 | St. Jude Children's Research Hospital, Inc. | Diagnostic and therapeutic uses for prox 1 |
| GB0509438D0 (en) | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| EP2056865B1 (en) * | 2006-08-28 | 2013-12-25 | Omnio Healer AB | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| CN101573134B (zh) * | 2006-08-28 | 2013-03-06 | 李季男 | 抗感染候选药物 |
| NZ597452A (en) * | 2009-07-10 | 2013-10-25 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| JP6343147B2 (ja) * | 2010-08-30 | 2018-06-13 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 狭窄病変および血栓溶解療法のための剪断による制御放出 |
| HUE068351T2 (hu) | 2014-12-19 | 2024-12-28 | Kedrion Biopharma Inc | Plazminogént tartalmazó gyógyszerkészítmény és annak felhasználásai |
| WO2017101870A1 (zh) * | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗糖尿病性视网膜病变的方法 |
-
2016
- 2016-11-02 TW TW105135535A patent/TWI801331B/zh active
- 2016-11-03 RU RU2018120182A patent/RU2736831C2/ru active
- 2016-11-03 MY MYPI2018000585A patent/MY199581A/en unknown
- 2016-11-03 BR BR112018008965A patent/BR112018008965A8/pt not_active Application Discontinuation
- 2016-11-03 CN CN201680067482.XA patent/CN108289935A/zh active Pending
- 2016-11-03 AU AU2016347863A patent/AU2016347863B2/en active Active
- 2016-11-03 FI FIEP16861682.9T patent/FI3370760T3/fi active
- 2016-11-03 KR KR1020187015657A patent/KR102821400B1/ko active Active
- 2016-11-03 JP JP2018522753A patent/JP6878423B2/ja active Active
- 2016-11-03 US US15/771,454 patent/US11291711B2/en active Active
- 2016-11-03 MX MX2018005588A patent/MX2018005588A/es unknown
- 2016-11-03 WO PCT/IB2016/001599 patent/WO2017077380A1/en not_active Ceased
- 2016-11-03 EP EP16861682.9A patent/EP3370760B1/en active Active
- 2016-11-03 CA CA3002915A patent/CA3002915C/en active Active
-
2018
- 2018-04-24 IL IL258913A patent/IL258913B/en unknown
- 2018-04-26 ZA ZA2018/02820A patent/ZA201802820B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533589A5 (enExample) | ||
| RU2018120182A (ru) | Плазминоген-заместительная терапия при дефиците плазминогена | |
| EP2635269B1 (en) | A combination composition | |
| JP2020033360A5 (enExample) | ||
| Kelly et al. | Beta-adrenergic agonists for acute, severe asthma | |
| Kumar et al. | The syndrome of irreversible acidosis after prolonged propofol infusion | |
| Khilnani et al. | Non-invasive ventilation after extubation in patients with chronic obstructive airways disease: a randomised controlled trial | |
| ES2971959T3 (es) | Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2013541583A5 (enExample) | ||
| King et al. | Bradycardia in a pediatric heart transplant recipient: is it the sugammadex? | |
| JP2018531605A5 (enExample) | ||
| AU2011274652B2 (en) | A combination composition comprising ibuprofen and paracetamol | |
| JP2020531568A5 (enExample) | ||
| JP2016510040A5 (enExample) | ||
| Fabi et al. | Are nasal decongestants safer than rhinitis? A case of oxymetazoline-induced syncope | |
| Yaman et al. | Neuroleptic malignant syndrome associated with metoclopramide in a child | |
| Akca et al. | Nebulized epinephrine treatment in pediatric emergency department | |
| Walsh et al. | A pediatric case study of treprostinil overdose | |
| EP3906934A1 (en) | Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections | |
| Graff et al. | Chloroquine Ingestion to Prevent SARS-CoV-2 Infection: A Report of Two Cases | |
| Iskit et al. | Pediatric Asthma Management | |
| Hwang et al. | Serotonin Syndrome Induced by Drug Interaction of Isoniazid and Metoclopramide | |
| Aranda et al. | Biodistribution Of [f-18] Fdg-Labeled Adult Bone Marrow-Derived Mesenchymal Stromal Cells With Pet/ct Scan In An Ards Sheep Model | |
| Haitsma et al. | Surfactant Therapy |